CN111295169A - 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物 - Google Patents

诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物 Download PDF

Info

Publication number
CN111295169A
CN111295169A CN201880061919.8A CN201880061919A CN111295169A CN 111295169 A CN111295169 A CN 111295169A CN 201880061919 A CN201880061919 A CN 201880061919A CN 111295169 A CN111295169 A CN 111295169A
Authority
CN
China
Prior art keywords
oil
composition
patient
compositions
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880061919.8A
Other languages
English (en)
Chinese (zh)
Inventor
斯科特·怀特卡普
奥雷斯特·欧莱伊尼克
迈克尔·加斯特
彼得·A·西蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akrivista LLC
Original Assignee
Akrivista LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akrivista LLC filed Critical Akrivista LLC
Priority to CN202111484102.1A priority Critical patent/CN114376961A/zh
Publication of CN111295169A publication Critical patent/CN111295169A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
CN201880061919.8A 2017-08-18 2018-08-17 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物 Pending CN111295169A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111484102.1A CN114376961A (zh) 2017-08-18 2018-08-17 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547553P 2017-08-18 2017-08-18
US62/547,553 2017-08-18
PCT/US2018/046918 WO2019036625A1 (en) 2017-08-18 2018-08-17 METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111484102.1A Division CN114376961A (zh) 2017-08-18 2018-08-17 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物

Publications (1)

Publication Number Publication Date
CN111295169A true CN111295169A (zh) 2020-06-16

Family

ID=65363005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880061919.8A Pending CN111295169A (zh) 2017-08-18 2018-08-17 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
CN202111484102.1A Pending CN114376961A (zh) 2017-08-18 2018-08-17 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111484102.1A Pending CN114376961A (zh) 2017-08-18 2018-08-17 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物

Country Status (7)

Country Link
US (2) US11622982B2 (enExample)
EP (1) EP3668474A4 (enExample)
JP (1) JP7311160B2 (enExample)
CN (2) CN111295169A (enExample)
BR (1) BR112020003276A2 (enExample)
CA (1) CA3072494A1 (enExample)
WO (1) WO2019036625A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112842936A (zh) * 2021-03-15 2021-05-28 傅博 一种眼部清洁液及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
BR112020003276A2 (pt) 2017-08-18 2020-09-01 Akrivista, LLC métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
EP3888634B1 (en) * 2020-03-31 2023-06-07 Oy Finnsusp Ab Ophthalmic formulation and its use
EP3919047A1 (en) 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
ES2916152A1 (es) * 2020-12-28 2022-06-28 Univ Valladolid Compuestos para su uso en la prevencion y/o tratamiento de la inflamacion y el estres oxidativo del segmento anterior del ojo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100174000A1 (en) * 2007-05-29 2010-07-08 Octalia Technologies Carrier in the form of oil-in-water emulsion notably intended for ophthalmic or dermocosmetic use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4146499A (en) 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
US4585656A (en) 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
CA2052950A1 (en) 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5527488A (en) * 1992-08-07 1996-06-18 Amway Corporation High viscosity anhydrous makeup remover gel
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US20030086986A1 (en) 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7262224B2 (en) * 1999-11-30 2007-08-28 Hanna Isul Skin Therapy, Inc. Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
MXPA04003299A (es) 2001-10-11 2004-07-23 Alcon Inc Metodos para tratar la resequedad ocular mediante una combinacion de un esteroide antiinflamatorio y un secretagogo muc-1.
US6559182B1 (en) 2001-11-07 2003-05-06 Purcell Jojoba International, Llc Method for treatment of enveloped viruses using jojoba oil esters
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
CA2559503A1 (en) 2004-03-12 2006-01-12 Melbj Holdings, Llc Lubricant for the ocular surface
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
JP5272307B2 (ja) 2004-07-16 2013-08-28 大正製薬株式会社 水性点眼剤
WO2006073786A2 (en) 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US9161905B2 (en) 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
JP2006233398A (ja) 2005-02-23 2006-09-07 Daiwa Kagaku Kogyo Kk アボガド油及びアボガド油不けん化物を処理したことを特徴とする機能化繊維材料および機能化繊維材料の処理方法。
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
CN101668511A (zh) 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
JP2012528888A (ja) 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド 眼科用配合剤、その製造方法およびその使用方法
HRP20171691T1 (hr) 2009-06-05 2017-12-15 Allergan, Inc. Umjetne suze i njihova upotreba u terapiji
JP5673531B2 (ja) 2009-06-30 2015-02-18 ライオン株式会社 眼科用組成物
US8909327B1 (en) 2010-06-23 2014-12-09 Allergan, Inc. Instrument and method for diagnosing dry eye in a patient
US20130331768A1 (en) 2010-12-29 2013-12-12 Louis D. Nichamin Eye treatment
US20140302146A1 (en) 2011-07-08 2014-10-09 Rohto Pharmaceutical Co.,Ltd. Ophthalmic Aqueous Composition
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
SG11201403013VA (en) * 2011-12-07 2014-07-30 Allergan Inc Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
JP5988855B2 (ja) 2012-06-27 2016-09-07 ロート製薬株式会社 水性眼科組成物
WO2015137357A1 (ja) 2014-03-10 2015-09-17 サラヤ株式会社 ソホロリピッドと生理活性物質と油脂とを含有する組成物およびその製造方法
UA121399C2 (uk) 2014-11-25 2020-05-25 Аллерган, Інк. Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
PL3266446T3 (pl) 2016-07-07 2019-05-31 Salvat Lab Sa Kompozycja oftalmiczna zawierająca olej rycynowy i trójgliceryd o średniej długości łańcucha
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
CN106389218A (zh) * 2016-10-28 2017-02-15 林振慧 一种眼部凝露
BR112020003276A2 (pt) 2017-08-18 2020-09-01 Akrivista, LLC métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100174000A1 (en) * 2007-05-29 2010-07-08 Octalia Technologies Carrier in the form of oil-in-water emulsion notably intended for ophthalmic or dermocosmetic use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112842936A (zh) * 2021-03-15 2021-05-28 傅博 一种眼部清洁液及其制备方法

Also Published As

Publication number Publication date
EP3668474A4 (en) 2021-05-26
US20230233637A1 (en) 2023-07-27
BR112020003276A2 (pt) 2020-09-01
CA3072494A1 (en) 2019-02-21
JP2020531462A (ja) 2020-11-05
EP3668474A1 (en) 2020-06-24
US20200164013A1 (en) 2020-05-28
WO2019036625A1 (en) 2019-02-21
US12220439B2 (en) 2025-02-11
CN114376961A (zh) 2022-04-22
US11622982B2 (en) 2023-04-11
JP7311160B2 (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
US12220439B2 (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
JP2022177281A (ja) ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
Yeu et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)
Tauber et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Benelli Systane® lubricant eye drops in the management of ocular dryness
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
CN111182893A (zh) 包含f6h8的眼用组合物
KR20210080388A (ko) 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
Fong et al. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
SA521430043B1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل
Martin et al. Effect of tear supplements on signs, symptoms and inflammatory markers in dry eye
CN103282044B (zh) 纳米乳剂形态的眼科用组合物
Labetoulle et al. Efficacy and safety of dual-polymer hydroxypropyl guar-and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
Burillon et al. Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
Hirneiß et al. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study
Yeu et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle
Wei et al. Antioxidant carbon dots nanozyme loaded in thermosensitive in situ hydrogel system for efficient dry eye disease treatment
Kaarniranta et al. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies
BR112021011210A2 (pt) Formulações oftálmicas que proporcionam lubrificação ocular durável
CN110013498A (zh) 一种含盐酸奥洛他定的滴眼液及其制备方法
HK40073074A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
HK40007121A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
CA3076567C (en) Ophthalmic compositions comprising f6h8
Mohapatra et al. Emulsion and Emulgel-Based Ophthalmic Drug Delivery Systems

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200616